Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary K Schwartz

Showing results (1-10 of 245) with videos related to

Pageof 25
Sort By:
Cell Cycle (Georgetown, Tex.)|November 14, 2002
CDK inhibitors: cell cycle arrest versus apoptosisGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2005
Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapyGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term SafetyGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Reply to S. Rastogi et alGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2022
Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision MedicineGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Trabectedin and the L-Sarcomas: A Decade-Long OdysseyGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Flashback Foreword: Adjuvant Interferon α-2b for High-Risk MelanomaGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
Cell-Cycle Therapeutics Come of AgeMatthew Ingham, Gary K Schwartz
Cancer Investigation|January 23, 2004
Bryostatin-1: a novel PKC inhibitor in clinical developmentJeremy Kortmansky, Gary K Schwartz
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
Cyclin-dependent kinases as targets for cancer therapyManish A Shah, Gary K Schwartz
Pageof 25

Showing results (1-10 of 245) with videos related to

Sort By:
Pageof 25
Cell Cycle (Georgetown, Tex.)|November 14, 2002
CDK inhibitors: cell cycle arrest versus apoptosisGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2005
Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapyGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term SafetyGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Reply to S. Rastogi et alGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2022
Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision MedicineGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Trabectedin and the L-Sarcomas: A Decade-Long OdysseyGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Flashback Foreword: Adjuvant Interferon α-2b for High-Risk MelanomaGary K Schwartz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
Cell-Cycle Therapeutics Come of AgeMatthew Ingham, Gary K Schwartz
Cancer Investigation|January 23, 2004
Bryostatin-1: a novel PKC inhibitor in clinical developmentJeremy Kortmansky, Gary K Schwartz
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
Cyclin-dependent kinases as targets for cancer therapyManish A Shah, Gary K Schwartz
Pageof 25